New study tracks heart risks of prostate cancer combo in japanese men

NCT ID NCT06010914

Ongoing Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study is collecting data from Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. The main goal is to track heart-related side effects and other safety issues in real-world settings. No extra tests or visits are required—just routine care data. The study runs from 2023 to 2026.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darolutamide
What this could lead to: If successful, this study could provide real-world safety information to support the use of darolutamide in combination with ADT and docetaxel for Japanese men with metastatic hormone-sensitive prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. It only collects data from routine care, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Locations

Many Locations

Multiple Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.